Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

6.205 -0.025 (-0.40%)
Streaming Delayed Price Updated: 3:05 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Jim Cramer: Joby Is 'Losing Too Much Money' ↗
Jim Cramer finds Aquestive Therapeutics very interesting, while Amphenol Corporation is a great stock. Joby Aviation is losing money. 
Via Benzinga
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Friday's session: gap up and gap down stocks ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA... 
Via Benzinga
Topics Stocks
Aquestive Stock Jumps After-Hours As CEO Sees $1B ‘Blockbuster’ Potential For Oral Allergy Film — Retail Sees Stock As Buyout Candidate ↗
Via Stocktwits
FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film ↗
Via Stocktwits
Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail ↗
Via Stocktwits
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment ↗
ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Friday? ↗
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Shoe Carnival, American Eagle, Ciena, Victoria's Secret And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
FDA Confirms Direct Review Path For Aquestive's Allergy Treatment ↗
Aquestive's Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decision date without panel review. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Uncovering Potential: Aquestive Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Uncovering Potential: Aquestive Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data ↗
Aquestive's Anaphylm sublingual film met key pediatric study goals, supporting its NDA submission to the FDA for potential approval in 2025. 
Via Benzinga
News headline image
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings ↗
Stocktwits users are viewing the company's cash position, expectations for a late 2026 Anaphylm launch, and an upcoming trial as positive signals. 
Via Stocktwits
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Earnings Scheduled For March 5, 2025 ↗
 
Via Benzinga
News headline image
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside ↗
Cantor initiates coverage on Aquestive Therapeutics, highlighting Anaphylm's potential to disrupt the epinephrine auto-injector market with 200% upside. 
Via Benzinga
News headline image
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate ↗
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... 
Via Benzinga
News headline image
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows ↗
Aquestive Therapeutics released topline pharmacokinetic data for Anaphylm (epinephrine) Sublingual Film for severe allergic reactions. 
Via Benzinga
News headline image
AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗
AQST stock results show that Aquestive Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.